These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11058713)

  • 1. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration.
    Totsuka M; Miyashita Y; Ito Y; Watanabe H; Murano T; Shirai K
    Atherosclerosis; 2000 Nov; 153(1):175-9. PubMed ID: 11058713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias.
    Watanabe H; Miyashita Y; Murano T; Hiroh Y; Itoh Y; Shirai K
    Atherosclerosis; 1999 Jul; 145(1):45-50. PubMed ID: 10428294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
    Saiki A; Ohira M; Endo K; Koide N; Oyama T; Murano T; Miyashita Y; Shirai K
    Diabetes Res Clin Pract; 2006 Dec; 74(3):242-8. PubMed ID: 16713009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of the serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: Comparison with postheparin plasma.
    Hirano T; Nishioka F; Murakami T
    Metabolism; 2004 Apr; 53(4):526-31. PubMed ID: 15045703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II.
    Kawaguchi A; Miyao Y; Noguchi T; Nonogi H; Yamagishi M; Miyatake K; Kamikubo Y; Kumeda K; Tsushima M; Yamamoto A; Kato H
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):251-8. PubMed ID: 10634826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of preheparin serum lipoprotein lipase mass in normocholesterolemic patients with coronary artery disease].
    Hitsumoto T; Yoshinaga K; Sakurai T; Aoyagi K; Matsumoto J; Iizuka T; Kaku M; Sugiyama Y; Kanai M; Uchi T; Noike H; Ohsawa H; Watanabe H; Shirai K
    J Cardiol; 2002 Jul; 40(1):1-9. PubMed ID: 12166243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preheparin lipoprotein lipolytic activities: relationship to plasma lipoproteins and postheparin lipolytic activities.
    Glaser DS; Yost TJ; Eckel RH
    J Lipid Res; 1992 Feb; 33(2):209-14. PubMed ID: 1569373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding.
    de Man FH; de Beer F; van der Laarse A; Jansen H; Leuven JA; Souverijn JH; Vroom TF; Schoormans SC; Fruchart JC; Havekes LM; Smelt AH
    Atherosclerosis; 2000 Dec; 153(2):363-71. PubMed ID: 11164425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of preheparin lipoprotein lipase mass as a parameter for predicting the efficacy of colestimide.
    Sasaki H; Kanai S; Oyama T; Miyashita Y; Shirai K
    J Atheroscler Thromb; 2005; 12(4):218-24. PubMed ID: 16141626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects.
    Norioka M; Suzuki M; Ryomoto K; Ikebuchi M; Harano Y
    J Atheroscler Thromb; 2000; 7(4):198-202. PubMed ID: 11521682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome.
    Saiki A; Oyama T; Endo K; Ebisuno M; Ohira M; Koide N; Murano T; Miyashita Y; Shirai K
    Diabetes Res Clin Pract; 2007 Apr; 76(1):93-101. PubMed ID: 16956692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins.
    Tornvall P; Olivecrona G; Karpe F; Hamsten A; Olivecrona T
    Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1086-93. PubMed ID: 7627700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins.
    Vilella E; Joven J; Fernández M; Vilaró S; Brunzell JD; Olivecrona T; Bengtsson-Olivecrona G
    J Lipid Res; 1993 Sep; 34(9):1555-64. PubMed ID: 8228638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy.
    Miyashita Y; Shirai K; Itoh Y; Sasaki H; Totsuka M; Murano T; Watanabe H
    Diabetes Res Clin Pract; 2002 Jun; 56(3):181-7. PubMed ID: 11947965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased serum triglyceride clearance and elevated high-density lipoprotein 2 and 3 cholesterol during treatment of primary hypertriglyceridemia with bezafibrate.
    Sakuma N; Ikeuchi R; Hibino T; Yoshida T; Mukai S; Akita S; Yajima K; Miyabe H; Goto T; Takada N; Ohte N; Kunimatu M; Kimura G
    Curr Ther Res Clin Exp; 2003 Nov; 64(9):697-706. PubMed ID: 24944417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparate effects of a triglyceride lowering diet and of bezafibrate on the HDL system: a study in patients with hypertriglyceridaemia and low HDL-cholesterol levels.
    Arnon R; Sehayek E; Eisenberg S
    Eur J Clin Invest; 1993 Aug; 23(8):492-8. PubMed ID: 8405002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
    Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y
    Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
    Brisson D; Ledoux K; Bossé Y; St-Pierre J; Julien P; Perron P; Hudson TJ; Vohl MC; Gaudet D
    Pharmacogenetics; 2002 Jun; 12(4):313-20. PubMed ID: 12042669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus.
    Sasaki H; Kanai S; Oyama T; Miyashita Y; Yamamura S; Shirai K
    J Atheroscler Thromb; 2006 Jun; 13(3):149-57. PubMed ID: 16835470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.